Medimmune Limited

Scott A Hammond

Melissa Marie Damschroder

Michelle Morrow

Michael Oberst

Ian Nevin Foltz

Jaspal Singh Kang

Ralph Raymond Minter

Lutz Jermutus

Sandrine Guillard

Ching Ching Leow

Carl Hay

Yariv Mazor

Peter Pavlik

Melanie Boyle

Matthieu Chodorge

Laura Sekirov

Robert E Hollingsworth

Erin Sult

Kris Sachsenmeier

Marat Alimzhanov

Nicholas Durham

Kim Rosenthal

Xiaojun Lu

Christophe Queva

Gundo Diedrich

Kathleen Ann Mulgrew

Mary Antonysamy

Steve Rust

Jonathan Rios-Doria

Li Cheng

Qihui Huang

James Geoghegan

Changshou Gao

Claire Louise Dobson

Ronald Herbst

Darren Schofield

Godfrey Rainey

Stacey Drabic

Srinath Kasturirangan

Ross Anthony Stewart

Brian Lobo

Prakash Manikwar

Simon Dovedi

Jonathan Seaman

Gianluca Carlesso

John Babcock

Kristen Pollizzi

Qun Du

John Stephen Babcook

Steven Rust

Ambarish Shah

Gordon Moody

Monika S Sharma, Sr

Ross A Steward

Hui Feng

Yue Wang

Deepali Malhotra

Michael Overstreet

Karin Lee

Stacy Pryts

Eleanor Clancy-thompson

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 ('PD-1') and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

Bispecific PD-1 and TIGIT binding proteins and uses thereof

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Binding molecules specific for CD73 and uses thereof

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Targeted binding agents against B7-H1

The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.

Method of treating cancer with humanized anti-OX40 antibodies

Humanized anti-OX40 antibodies and uses thereof

The disclosure provides OX40L huIgG4 fusion polypeptide subunits comprising a human IgG4 Fc domain, a trimerization domain, and the receptor binding domain of Ox40 ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.

OX40L fusion proteins and uses thereof

The present invention provides stable lyophilized formulations of bispecific antibodies or fragments thereof.

Protein formulation

Growing community of inventors

Gaithersburg, MD, United States of America

Scott A Hammond